Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean ‘분기보고서’ (Quarterly Report) for the 51st period covering January 1, 2026 to March 31, 2026. It contains detailed sections including company overview, business content, full financial statements and notes, dividend information, stock capital details, management analysis, and auditor opinions. This is a substantive interim/quarterly financial report rather than an announcement or summary, fitting the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a Korean “주식등의 대량보유상황보고서(일반)” form detailing the large shareholding situation of the company’s major shareholder and related parties. It itemizes share counts, percentages, changes, contractual arrangements, and relationships under the Capital Markets Act. This matches the definition of a Major Shareholding Notification, which is Code MRQ.
2026-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a formal announcement of the results of the company’s regular general meeting (정기주주총회 결과), detailing approved agenda items, voting outcomes for approval of financial statements, dividend resolutions, board and auditor appointments, vote tallies, and related record dates. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-30 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 55% confidence The document is a voluntary regulatory disclosure (“자율공시”) by a Korean-listed company outlining a corporate value enhancement plan, including projected R&D, sales targets, dividend policy, and share cancellation. It does not contain financial results (so it’s not an ER or IR report), no detailed management discussion of past financials (MDA), nor major shareholding changes (MRQ), nor specific share issuance or buyback program (POS). It’s also not an AGM or proxy statement, dividend notice, or a presentation. This falls into the miscellaneous regulatory filings category.
2026-03-30 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the 50th fiscal year (2025.01.01-2025.12.31) of KyungDong Pharmaceutical Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, governance information, and detailed operational data. In the context of Korean corporate filings, this is the equivalent of a 10-K Annual Report. FY 2025
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Kyungdong Pharmaceutical. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and confirms the receipt of the audit report from the external auditor (Han Young Accounting Corp). While it contains financial data, it is a standard regulatory disclosure announcement required by the KRX (Korea Exchange) when an audit report is finalized, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.